UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Olaparib for Metastatic Castration-Resistant Prostate Cancer

The New England journal of medicine, 2020-05, Vol.382 (22), p.2091-2102

2020

Link zum Volltext

Verfügbarkeit prüfen

Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer

Journal of clinical oncology, 2014-03, Vol.32 (7), p.671-677

2014

Link zum Volltext

Verfügbarkeit prüfen

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer

The New England journal of medicine, 2019-12, Vol.381 (26), p.2506-2518

2019

Link zum Volltext

Verfügbarkeit prüfen

Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer

The New England journal of medicine, 2020-06, Vol.382 (23), p.2197-2206

2020

Link zum Volltext

Verfügbarkeit prüfen

Phase III, Randomized, Placebo-Controlled Study of Docetaxel in Combination With Zibotentan in Patients With Metastatic Castration-Resistant Prostate Cancer

Journal of clinical oncology, 2013-05, Vol.31 (14), p.1740-1747

2013

Link zum Volltext

Verfügbarkeit prüfen

Targeting continued androgen receptor signaling in prostate cancer

Clinical cancer research, 2011-06, Vol.17 (12), p.3876-3883

2011

Link zum Volltext

Verfügbarkeit prüfen

Immunotherapy discontinuation - how, and when? Data from melanoma as a paradigm

Nature reviews. Clinical oncology, 2020-11, Vol.17 (11), p.707-715

2020

Link zum Volltext

Verfügbarkeit prüfen

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

The New England journal of medicine, 2019-03, Vol.380 (13), p.1235-1246

2019

Link zum Volltext

Verfügbarkeit prüfen

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

The New England journal of medicine, 2020-12, Vol.383 (24), p.2345-2357

2020

Link zum Volltext

Verfügbarkeit prüfen

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

The New England journal of medicine, 2017-07, Vol.377 (4), p.352-360

2017

Link zum Volltext

Verfügbarkeit prüfen

Androgen Deprivation Therapy and Secondary Hormone Therapy in the Management of Hormone-sensitive and Castration-resistant Prostate Cancer

Urology (Ridgewood, N.J.), 2015-11, Vol.86 (5), p.852-861

2015

Link zum Volltext

Verfügbarkeit prüfen

Abiraterone and Increased Survival in Metastatic Prostate Cancer

The New England journal of medicine, 2011-05, Vol.364 (21), p.1995-2005

2011

Link zum Volltext

Verfügbarkeit prüfen

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology

European urology, 2019-01, Vol.75 (1), p.88-99

2019

Link zum Volltext

Verfügbarkeit prüfen

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer

The New England journal of medicine, 2022-03, Vol.386 (12), p.1132-1142

2022

Link zum Volltext

Verfügbarkeit prüfen

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

The New England journal of medicine, 2014-07, Vol.371 (5), p.424-433

2014

Link zum Volltext

Verfügbarkeit prüfen

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

The New England journal of medicine, 2012-09, Vol.367 (13), p.1187-1197

2012

Link zum Volltext

Verfügbarkeit prüfen

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

The lancet oncology, 2014-06, Vol.15 (7), p.700-712

2014

Link zum Volltext

Verfügbarkeit prüfen

Genetic characterization of a unique neuroendocrine transdifferentiation prostate circulating tumor cell-derived eXplant model

Nature communications, 2020-04, Vol.11 (1), p.1884-1884, Article 1884

2020

Link zum Volltext

Verfügbarkeit prüfen

Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer

Journal of clinical oncology, 2017-09, Vol.35 (27), p.3097-3104

2017

Link zum Volltext

Verfügbarkeit prüfen

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

Journal of clinical oncology, 2016-04, Vol.34 (12), p.1402-1418

2016

Link zum Volltext

Verfügbarkeit prüfen

Carcinomas of an unknown primary origin--diagnosis and treatment

Nature reviews. Clinical oncology, 2011-12, Vol.8 (12), p.701-710

2011

Link zum Volltext

Verfügbarkeit prüfen

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

The lancet oncology, 2015-02, Vol.16 (2), p.152-160

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 726

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(713)
Mit Volltextzugriff
(691)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(347)
Life Sciences & Biomedicine
(346)
Humans
(312)
Male
(291)
Oncology
(237)
Prostate Cancer
(142)
Middle Aged
(137)
Aged
(128)
Prostatic Neoplasms, Castration-Resistant - Drug Therapy
(109)
Urology & Nephrology
(105)
Treatment Outcome
(96)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(82)
Chemotherapy
(79)
Biological And Medical Sciences
(78)
Medical Sciences
(78)
Prostatic Neoplasms, Castration-Resistant - Pathology
(77)
Metastasis
(74)
Disease-Free Survival
(71)
Tumors
(71)
Adult
(69)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(303)
European Urology
(71)
European Journal Of Cancer
(50)
The Lancet Oncology
(27)
The New England Journal Of Medicine
(21)
Cancer Research
(20)
Bulletin Du Cancer
(18)
Clinical Cancer Research
(18)
Cancer
(13)
Clinical Genitourinary Cancer
(12)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(15)

Menü

Weitere Dienste

Einstellungen

Olaparib for Metastatic Castration-Resistant Prostate Cancer

Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer

Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer

Phase III, Randomized, Placebo-Controlled Study of Docetaxel in Combination With Zibotentan in Patients With Metastatic Castration-Resistant Prostate Cancer

Targeting continued androgen receptor signaling in prostate cancer

Immunotherapy discontinuation - how, and when? Data from melanoma as a paradigm

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

Androgen Deprivation Therapy and Secondary Hormone Therapy in the Management of Hormone-sensitive and Castration-resistant Prostate Cancer

Abiraterone and Increased Survival in Metastatic Prostate Cancer

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer

Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

Genetic characterization of a unique neuroendocrine transdifferentiation prostate circulating tumor cell-derived eXplant model

Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial

Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial

Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

Carcinomas of an unknown primary origin--diagnosis and treatment

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

Suchergebnisse filtern